Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 27;4(4):32.
doi: 10.3390/dj4040032.

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma

Petra Rugani  1 , Christian Walter  2 , Barbara Kirnbauer  3 , Stephan Acham  4 , Yvonne Begus-Nahrman  5 , Norbert Jakse  6
Affiliations
Review

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma

Petra Rugani et al. Dent J (Basel). .

Abstract

Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.

Keywords: bisphosphonate; breast cancer; denosumab; multiple myeloma; osteonecrosis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Published prevalences.
Figure 2
Figure 2
Published prevalences in reports until 2009 and since 2010.
See this image and copyright information in PMC

References

    1. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003;61:1115–1117. doi: 10.1016/S0278-2391(03)00720-1. - DOI - PubMed
    1. Tarassoff P., Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J. Oral Maxillofac. Surg. 2003;61:1238–1239. doi: 10.1016/j.joms.2003.09.001. - DOI - PubMed
    1. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E., Mehrotra B., American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J. Oral Maxillofac. Surg. 2009;67:S2–S12. - PubMed
    1. Ziebart T., Pabst A., Klein M.O., Kammerer P., Gauss L., Brullmann D., Al-Nawas B., Walter C. Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin. Oral Investig. 2011;15:105–111. doi: 10.1007/s00784-009-0365-2. - DOI - PubMed
    1. Hoefert S., Schmitz I., Tannapfel A., Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: A possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin. Oral Investig. 2010;14:271–284. doi: 10.1007/s00784-009-0300-6. - DOI - PubMed

LinkOut - more resources